Rare diseases
Investigational molecules
Locations
Efficacy and Safety of ALKS 2680 and Alixorexton in Adults with Narcolepsy Type 1
AustriaPhase 3 Randomized, Double‑Blind, Placebo‑Controlled Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 2
AustriaPhase 3 Randomized Study of ALKS 2680 for Excessive Daytime Sleepiness in Adults with Narcolepsy Type 1
AustriaLong-Term Study on the Safety and Effects of ALKS 2680 for Patients with Narcolepsy Type 1 and Type 2
BelgiumStudy of ALKS 2680 to treat excessive daytime sleepiness in people with idiopathic hypersomnia
BelgiumStudy on the Safety and Effectiveness of ALKS 2680 for Patients with Narcolepsy Type 2
BelgiumStudy on the Safety and Effectiveness of ALKS 2680 for Patients with Narcolepsy Type 1
BelgiumTell us about your condition – we search every trial in Europe and connect you with the right site.
